Compare iShares Core US Aggregate Bond ETF (AGG) vs Davita Inc (DVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs Davita Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $98.06, while Davita Inc trades at $231.67 (market cap $15.04B). The key difference: Davita Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | DVA | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $235.71 |
52-Week Low | $97.63 | $103.87 |
Market Cap | — | $15.04B |
Enterprise Value | — | $27.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.
DaVita (DVA) trades at $234.31, showing modest daily decline but maintaining strong momentum near 52-week highs. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth continues with $13.64B in 2025, while net margins of 5.65% reflect steady profitability. Recent news highlights DVA's expansion in kidney care delivery and AI-driven scheduling improvements, positioning the company for continued growth in specialized healthcare services.
Investment outlook remains positive with analyst consensus favoring Buy ratings (39%) and price targets averaging $211. Key opportunities include expanding kidney care services and operational efficiencies, while risks involve high debt levels (65.55% debt-to-asset ratio) and healthcare regulatory pressures. Current valuation metrics (P/E 22.71, P/S 1.24) appear reasonable given growth prospects, though the stock trades above consensus targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
